SUPERNUS PHARMACEUTICALS, INC. (SUPN) FY2026 Q2 Statement of Cash Flows

Statement of Cash Flows

2026-04-01 to 2026-06-30

Swipe to see the full flow
SUPERNUS PHARMACEUTICALS, INC. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Maturities of marketable securities → investing reconciliation: $57,662,000.00investing reconciliation → Net cash from investing activities: $7,094,000.00investing reconciliation → Purchases of marketable securities: $50,000,000.00investing reconciliation → Purchases of property and equipment: $568,000.00Proceeds from issuance of common stock → financing reconciliation: $4,123,000.00Net cash used in financing activities → financing reconciliation: $7,200,000.00financing reconciliation → Payment of contingent consideration: $11,235,000.00financing reconciliation → Employee taxes paid related to net share settlement of equity awards: $88,000.00Net cash used in operating activities → operating reconciliation: $4,810,000.00Intangible asset impairment charges → operating reconciliation: $54,919,000.00Depreciation and amortization → operating reconciliation: $25,747,000.00Prepaid expenses and other assets → operating reconciliation: $21,659,000.00Accrued product returns and rebates → operating reconciliation: $9,124,000.00Share-based compensation expense → operating reconciliation: $8,640,000.00Inventory valuation write-down → operating reconciliation: $4,049,000.00Noncash lease expense → operating reconciliation: $2,196,000.00Other noncash adjustments, net → operating reconciliation: $294,000.00operating reconciliation → Net earnings (loss): $58,371,000.00operating reconciliation → Accounts receivable: $29,474,000.00operating reconciliation → Payment of contingent consideration: $22,208,000.00operating reconciliation → Deferred income tax benefit: $16,949,000.00operating reconciliation → Accounts payable and other liabilities: $3,790,000.00operating reconciliation → Amortization of premium/discount on marketable securities: $340,000.00operating reconciliation → Inventories: $306,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $186,319,000.00Net cash from investing activities → Cash sources and uses: $7,094,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $181,403,000.00Cash sources and uses → Net cash used in financing activities: $7,200,000.00Cash sources and uses → Net cash used in operating activities: $4,810,000.00Net earnings (loss): -$58,371,000.00Net earnings (loss)−$58.37 MDepreciation and amortization: $25,747,000.00Depreciation & amortization+$25.75 MIntangible asset impairment charges: $54,919,000.00Intangible impairments+$54.92 MAmortization of premium/discount on marketable securities: -$340,000.00Securities accretion, net−$340.00 KChange in fair value of contingent consideration: $0.00Realized loss (gain) from sale of marketable securities: $0.00Share-based compensation expense: $8,640,000.00Stock-based compensation+$8.64 MDeferred income tax benefit: -$16,949,000.00Deferred income taxes−$16.95 MNoncash lease expense: $2,196,000.00Operating lease amortization+$2.20 MInventory valuation write-down: $4,049,000.00Inventory write-downs+$4.05 MPayment of contingent consideration: -$22,208,000.00Contingent consideration paid−$22.21 MOther noncash adjustments, net: $294,000.00Other non-cash items+$294.00 KAccounts receivable: -$29,474,000.00Accounts receivable−$29.47 MInventories: -$306,000.00Inventories−$306.00 KPrepaid expenses and other assets: $21,659,000.00Prepaid & other assets+$21.66 MAccrued product returns and rebates: $9,124,000.00Accrued returns & rebates+$9.12 MAccounts payable and other liabilities: -$3,790,000.00Payables & accrued liabilities−$3.79 MNet cash used in operating activities: -$4,810,000.00. Cash required to fund net payments.Operating cash−$4.81 Moperating reconciliation: $131,438,000.00Proceeds from issuance of common stock: $4,123,000.00Common stock issued+$4.12 MEmployee taxes paid related to net share settlement of equity awards: -$88,000.00Stock-award tax withholding−$88.00 KPayment of contingent consideration: -$11,235,000.00Contingent consideration paid−$11.24 MNet cash used in financing activities: -$7,200,000.00. Cash required to fund net payments.Financing cash−$7.20 Mfinancing reconciliation: $11,323,000.00Purchases of marketable securities: -$50,000,000.00AFS securities purchases−$50.00 MMaturities of marketable securities: $57,662,000.00AFS securities maturities+$57.66 MPurchases of property and equipment: -$568,000.00PP&E purchases−$568.00 KNet cash from investing activities: $7,094,000.00Investing cash+$7.09 Minvesting reconciliation: $57,662,000.00Cash sources and uses: $193,413,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $186,319,000.00Beginning cash$186.32 MEnding cash: Cash, cash equivalents, and restricted cash: $181,403,000.00Ending cash$181.40 MCASH RECONCILIATIONInvestingflowsFinancingflowsOperatingflowsNet loss −$58.37M + net operating adjustments $53.56M = operating cash −$4.81MFree cash flow−$5.38 MOperating cash − cash spent on PP&ECash flow / Net incomeNot meaningfulOperating cash flow ÷ net incomeNet cash change−$4.92 MEnding cash − beginning cash
Chart details

SUPERNUS PHARMACEUTICALS, INC. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026

Cash flows for Apr 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Mar 31, 2026. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Mar 31, 2026
186,319,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
negative 4,810,000 US dollars. Net cash used.
Net earnings (loss)
negative 58,371,000 US dollars
Depreciation and amortization
25,747,000 US dollars
Intangible asset impairment charges
54,919,000 US dollars
Amortization of premium/discount on marketable securities
negative 340,000 US dollars
Change in fair value of contingent consideration
0 US dollars
Realized loss (gain) from sale of marketable securities
0 US dollars
Share-based compensation expense
8,640,000 US dollars
Deferred income tax benefit
negative 16,949,000 US dollars
Noncash lease expense
2,196,000 US dollars
Inventory valuation write-down
4,049,000 US dollars
Payment of contingent consideration
negative 22,208,000 US dollars
Other noncash adjustments, net
294,000 US dollars
Accounts receivable
negative 29,474,000 US dollars
Inventories
negative 306,000 US dollars
Prepaid expenses and other assets
21,659,000 US dollars
Accrued product returns and rebates
9,124,000 US dollars
Accounts payable and other liabilities
negative 3,790,000 US dollars
Investing activities
7,094,000 US dollars. Net cash provided.
Purchases of marketable securities
negative 50,000,000 US dollars
Maturities of marketable securities
57,662,000 US dollars
Purchases of property and equipment
negative 568,000 US dollars
Financing activities
negative 7,200,000 US dollars. Net cash used.
Proceeds from issuance of common stock
4,123,000 US dollars
Employee taxes paid related to net share settlement of equity awards
negative 88,000 US dollars
Payment of contingent consideration
negative 11,235,000 US dollars
Operating adjustment reconciliation
131,438,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
11,323,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
57,662,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
0 US dollars
Ending cash on Jun 30, 2026
181,403,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
193,413,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
negative 4,916,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
Not meaningful. Operating cash flow divided by reconciliation net income for the same period. The ratio is not meaningful when net income is zero or negative.
Operating cash flow
negative 4,810,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
568,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
negative 5,378,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net loss −$58.37M + net operating adjustments $53.56M = operating cash −$4.81M. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: negative 4,810,000 US dollars minus 568,000 US dollars equals negative 5,378,000 US dollars.
SUPERNUS PHARMACEUTICALS, INC. (SUPN) FY2026 Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!